Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and He...
18 Mai 2020 - 9:05AM
Champignon Brands Inc. (“
Champignon” or the
“
Company”)
(CSE: SHRM) (FWB: 496) (OTCQB:
SHRMF), a human optimization sciences Company with an
emphasis on ketamine and psychedelic medicine, is pleased to
sponsor TheraPsil, a BC-based non-profit coalition of healthcare
professionals, policy-makers and community leaders (the
“
TheraPsil Coalition”) seeking legal access to
psilocybin for British Columbians with a palliative diagnosis and
psychological distress.
Operating at highest standards of clinical competence and
ethical integrity, the TheraPsil coalition is starting in 2020 with
seeking legal access to psilocybin for British Columbians with a
palliative diagnosis and psychological distress.
Based in Victoria, British Columbia and established in 2019,
TheraPsil is focused on:
- Compassionate Access: Establishing safe, and legal access to
psychedelic-assisted therapy for those in medical need;
- Public Education: Increasing awareness of the merits and
limitations of psychedelic-assisted therapy;
- Professional Training: Developing safe, simple and effective
protocols for credentialed health professionals to deliver
psilocybin-assisted therapy, in collaboration with other active
organizations; and,
- Research: Facilitate research and evaluation in collaboration
with Canadian and international partners.
“We’re really happy to have this support to get the ball rolling
on this project to help palliative Canadians. We are dedicated to
giving those at end-of-life the treatment options they deserve -
and that includes psilocybin. We believe that as a non-profit, and
with the right support, we can get these patients their right to
treatment with psilocybin in a timely manner,” Dr. Bruce Tobin,
founder of TheraPsil.
“Through our sponsorship, the Champignon team and board are
extremely proud to begin collaborating alongside TheraPsil, helping
patients in palliative care access new and effective therapies,”
said Pat McCutcheon, Director, Champignon. “Together we will work
to provide countless Canadians facing a palliative cancer
diagnosis, along with their families, who also face severe
psychological distress, with the treatment options, compassion and
hope they deserve.”
For information about the TheraPsil’s medical team and program,
visit www.therapsil.ca.
About Champignon Brands Inc.
Champignon Brands (CSE: SHRM) is focused on the formulation and
manufacturing of novel ketamine, anaesthetics and adaptogenic
delivery platforms for the nutraceutical and psychedelic medicine
while being supported by a leading psychedelics medicines clinic
platform. The Company is pursuing the development and
commercialization of rapid onset treatments capable of improving
health outcomes, such as depression and post-traumatic stress
disorder (PTSD), as well as substance and alcohol use disorders.
Under a collaborative research agreement with the University of
Miami's Miller School of Medicine, the Company is conducting
preclinical studies and eventual human clinical trials, with the
objective of demonstrating safety and efficacy of the combination
of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by
sustainability, as its medicinal mushroom-infused SKUs are organic,
non-GMO and vegan certified. For more information, visit the
Company’s website at: https://champignonbrands.com/.
ON BEHALF OF THE BOARD OF DIRECTORS
Dr. Roger McIntyre Chief Executive Officer T: +1 (613)
967-9655E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Tyler Troup Circadian Group
E: SHRM@champignonbrands.com
FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy ScalabriniMaricom Inc.E: rs@maricom.ca T: (888)
585-MARI
The CSE and Information Service Provider have
not reviewed and does not accept responsibility for the accuracy or
adequacy of this release.
Forward-looking Information Cautionary
Statement
Except for statements of historic fact, this
news release contains certain "forward-looking information" within
the meaning of applicable securities law. Forward-looking
information is frequently characterized by words such as "plan",
"expect", "project", "intend", "believe", "anticipate", "estimate"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements are
based on the opinions and estimates at the date the statements are
made, and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking statements
including, but not limited to delays or uncertainties with
regulatory approvals, including that of the CSE. There are
uncertainties inherent in forward-looking information, including
factors beyond the Company’s control. There are no assurances that
the business plans for Champignon Brands described in this news
release will come into effect on the terms or time frame described
herein. The Company undertakes no obligation to update
forward-looking information if circumstances or management's
estimates or opinions should change except as required by law. The
reader is cautioned not to place undue reliance on forward-looking
statements. Additional information identifying risks and
uncertainties that could affect financial results is contained in
the Company’s filings with Canadian securities regulators, which
are available at www.sedar.com.
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Champignon Brands (CSE:SHRM)
Historical Stock Chart
Von Dez 2023 bis Dez 2024